COMMUNIQUÉS West-GlobeNewswire

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
17/03/2025
SAN DIEGO and TORONTO, March 17, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based [...]
ProKidney Reports Full Year 2024 Financial Results and Business Highlights
17/03/2025
Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel’s path to market in the U.S., the release of positive Phase 2 data, restarting manufacturing, and securing $140 [...]
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
17/03/2025
–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March [...]
Kraig Biocraft Laboratories Confirms Operations in Vietnam's Silk Production Hub, Lam Dong Province
17/03/2025
ANN ARBOR, Mich., March 17, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk manufacturing, is pleased to confirm it has established [...]
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
17/03/2025
sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney condition and a [...]
Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Supporting Development of BIO 300 for the Prevention of Acute Radiation Syndrome
17/03/2025
Humanetics’ Novel Radioprotective Agent Being Developed with Funding from Department of Defense as Radiation Medical Countermeasure (MCM) Lifecore to Carry Out Tech Transfer and Analytical Method Activities, including [...]
Microbix & ACPCC support efforts to eliminate cervical cancer in the Indo-Pacific
17/03/2025
EPICC HPV Elimination Partnership being supplied PROCEEDxFLOQ QAPs to Support Test Accuracy MISSISSAUGA, Ontario and MELBOURNE, Australia, March 17, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: [...]
Spectral AI Announces Successful Results from its Burn Validation Study of the DeepView System
17/03/2025
DeepView ® System outperforms burn physicians in identifying non-healing tissue Landmark Burn Validation Study, one of the largest in U.S. history, confirms DeepView’s performance Spectral AI plans FDA submission by mid [...]
Collegium Announces Updates to its Board of Directors and Executive Leadership Team
17/03/2025
– Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board – – Dr. Carlos Paya Nominated to Board of Directors – – New Executives [...]
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
17/03/2025
WATERTOWN, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious [...]
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia
17/03/2025
Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström Macroglobulinemia First-in-class Bruton’s tyrosine kinase (BTK) degrader NX-5948 assigned nonproprietary [...]
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01
17/03/2025
STAFFORD, Texas, March 17, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
17/03/2025
Following a pre-specified interim analysis, the Data Safety Monitoring Board (DSMB) recommended the DRAGON trial, a pivotal Phase 3 trial in adolescent Stargardt 1 (STGD1) subjects, proceed without any modification; [...]
Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech
17/03/2025
March 17 th , 2025 Taiho Pharmaceutical Co., Ltd. Araris Biotech AG Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho [...]
Anocca Announces Authorisation of Clinical Trial Application to Start First In-Human Trial in Advanced Pancreatic Cancer
17/03/2025
CTA approval marks Anocca’s transition to a clinical-stage company First-in-human VIDAR-1 trial begins with the deployment of ANOC-001 in Advanced Pancreatic Cancer at leading medical centres in Sweden, Denmark, Germany [...]
Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody® Pipeline and Platform
17/03/2025
Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody ® Pipeline and Platform Financing led by General Catalyst with additional investment from new [...]
Celex Oncology Announce Novel Mechanism in Cancer Care and Attendance at Bio-Europe Spring 2025
17/03/2025
LONDON, March 17, 2025 (GLOBE NEWSWIRE) -- Celex Oncology, a UK biotechnology company founded in 2017 and on the brink of launching the fourth revolution in cancer care, today announced the Celex model and investigative [...]
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
17/03/2025
Press release – No. 4 / 2025 Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Phase 2b ZUPREME-1 [...]
EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition
17/03/2025
Acquisition includes EsoBiotec’s world-leading in vivo delivery platform with potential to transform cell therapy MONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE NEWSWIRE) -- EsoBiotec SA , a biotechnology company [...]

Pages